Navigation Links
Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
Date:6/1/2009

New Device Significantly Simplifies the Treatment of Abdominal Aortic Aneurysms

IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX) today announced the full commercial launch of the InutiTrak(TM) Express Delivery System for the endovascular treatment of large neck abdominal aortic aneurysms (AAA). The IntuiTrak family of devices features low profile, minimally invasive endovascular delivery systems that enhance vascular accessibility and maneuverability while simplifying the deployment of the Company's Powerlink stent graft products. As the newest addition to the IntuiTrak platform, IntuiTrak Express incorporates novel design and deployment features that enable the delivery of the Powerlink XL stent graft through the IntuiTrak 19Fr introducer sheath. This is the lowest profile delivery system currently available in the US for the endovascular repair of AAA in patients with aortic necks up to 32mm in diameter.

John McDermott, President and CEO of Endologix, said, "IntuiTrak Express expands our portfolio into a comprehensive suite of products that address a broad range of patient anatomies and physician preferences. Most importantly, it allows physicians to easily deliver and deploy our Powerlink XL stent graft through a single 19Fr introducer sheath, which has demonstrated the potential to reduce procedure times while minimizing blood loss and vessel trauma. We believe this will allow us to gain a greater share of physicians' AAA procedures based upon the ease of use and strong clinical outcomes achieved in patients with large aortic necks and other AAA anatomies. Early physician feedback on IntuiTrak Express was very positive during its limited release, so we accelerated the full commercial launch ahead of our original guidance to launch in the third quarter of this year."

The IntuiTrak Express Delivery System will be featured from June 11-14, 2009 at the Annual Meeting of the Society for Vascular Surgery (SVS) in Denver, Colorado. The Company's complete product portfolio will also be on display at the SVS meeting in the Company's booth #625.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to the full commercialization of the IntuiTrak Express Delivery System for the Powerlink XL, accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.


    COMPANY CONTACT:                      INVESTOR CONTACTS:
    ----------------                      ------------------
    Endologix, Inc.                       The Ruth Group
    John McDermott, CEO                   Nick Laudico (646) 536-7030
    (949) 595-7200                        Zack Kubow (646) 536-7020
    www.endologix.com


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... TX (PRWEB) , ... February 12, 2016 , ... The ... and other communities across eastern Texas, is launching a cooperative charity drive with the ... families. , Serving more than 50,000 individuals and families in need, the Tarrant County ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited to ... Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal implants ... the first office to be chosen by the dental implant manufacturer, Straumann, to bring ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. ... and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans ... categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors ...
(Date:2/12/2016)... LUIS OBISPO, Calif. (PRWEB) , ... February 12, 2016 , ... The Central Coast Autism ... of this dance is to provide a night of fun for teens with and without ... help everyone feel welcomed and included at the event. The dance will take place on ...
(Date:2/12/2016)... Sacramento CA (PRWEB) , ... February 12, 2016 , ... With the exception of restorative ... progression of dental decay. With the recent approval by the FDA, there is a ... application similar to fluoride varnish, SDF is very simple and quick to apply. The ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... VIEJO , Kalifornien, 12. Februar 2016 /PRNewswire/ ... mit der Aufnahme von Patienten für eine Studie ... von Aneurysmen („WEB") speziell für die Behandlung von ... Spelle , MD, Leiter der Neuroradiologie an der ... Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ersten ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... 12 februari 2016 AAIPharma Services ... leverancier van productie en ontwikkeling op maat ... vandaag een uitbreiding aan van steriele vul- ... in Charleston, SC . ... meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
Breaking Medicine Technology: